low blood pressure on tirzepatide New Study Finds Use Lowered in Patients with Obesity Tirzepatide and Blood Pressure: Your

BPC-157 cream-treated mice achieved complete re-epithelialization by day 14, while untreated controls and those receiving only vehicle cream showed poor re-epithelialization ratios at the same timepoint

In a study of more than 3,000 adults with obesity, the highest dose of orforglipron resulted in an average weight loss of 27.3 pounds over 72 weeks, with a safety profile consistent with injectable GLP-1s

The 8mg dose produces 21.1% average weight loss compared to 24.2% at 12mg

Of note, tirzepatide is not recommended for patients with severe gastrointestinal disease, including severe gastroparesis

Choose IV therapy when you want hydration or a broader infusion

Because retatrutide remains unlicensed, its full side-effect profile is still being characterised